--- title: "U.S. stock market midday update: Vor BioPharma's stock price soared 10.87%, J.P. Morgan conference boosts market confidence" type: "News" locale: "en" url: "https://longbridge.com/en/news/271695676.md" description: "Vor BioPharma rose 10.87%; AbbVie rose 1.68%, with a transaction volume of USD 907 million; Fortress Biotech rose 4.25%, with a transaction volume of USD 680 million; Amgen rose 2.93%, with a transaction volume of USD 523 million; Gilead Sciences rose 2.90%, with a market capitalization of USD 151 billion" datetime: "2026-01-06T20:37:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271695676.md) - [en](https://longbridge.com/en/news/271695676.md) - [zh-HK](https://longbridge.com/zh-HK/news/271695676.md) --- # U.S. stock market midday update: Vor BioPharma's stock price soared 10.87%, J.P. Morgan conference boosts market confidence **U.S. Stock Market Midday Update** Vor BioPharma rose 10.87%. Based on recent key news: 1. On January 6, Vor Biopharma announced it would participate in the 44th J.P. Morgan Healthcare Conference and hold an investor meeting. This news boosted market confidence in the company's future development, driving the stock price up by 10.87%. Source: GlobeNewswire 2. No other significant news recently. The healthcare industry conferences are active, with attention on policy changes. **Stocks with High Trading Volume in the Industry** AbbVie rose 1.68%. Based on recent key news: 1. On January 5, AbbVie announced it would participate in the JP Morgan Healthcare Conference, which is expected to attract investor attention. The company's management will discuss at the conference, potentially having a positive impact on the stock price. 2. On January 6, analyst ratings showed AbbVie received a "Moderate Buy" rating but was not included in the top recommended stocks list, which may affect investor confidence. 3. On January 4, merger and acquisition activities in the biopharmaceutical industry were active, and AbbVie, as a significant player in the industry, may benefit from the M&A wave. The biopharmaceutical industry is active in mergers and acquisitions, with a focus on rare diseases. Vertex Pharmaceuticals rose 4.25%. Based on recent key news: 1. On January 6, Wolfe Research upgraded Vertex Pharmaceuticals from Peer Perform to Outperform, setting a target price of $548. This rating upgrade enhanced market confidence in the biopharmaceutical industry, driving Vertex Pharmaceuticals' stock price up. 2. On January 4, MarketBeat noted that although Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top analysts believe there are five stocks that are more worthy of investment. This change in market sentiment may have affected investor interest in Vertex Pharmaceuticals. 3. On January 6, analysts predicted that large biopharmaceutical companies would grow approximately 8% annually over the next three years and become a viable alternative in the technology sector. This forecast raised market expectations for Vertex Pharmaceuticals, promoting an increase in stock price. The biopharmaceutical industry has performed strongly recently, with significant capital inflow. Amgen rose 2.93%. Based on recent news: 1. On January 6, Amgen announced it would acquire UK cancer drug developer Dark Blue for $840 million, aiming to expand its oncology product line. This move is seen as a significant strategic investment for the company in the field of targeted protein degradation and leukemia treatment, driving the stock price up. 2. On January 6, Amgen stated that Dark Blue's main candidate drug DBT 3757 showed strong anti-cancer activity in various leukemia models, further enhancing market confidence in its future growth On January 6, analysts generally believe that this acquisition will help Amgen open up new growth avenues in the face of competitive pressure from existing products, enhancing investor optimism. The biopharmaceutical industry has performed strongly recently, with investors focusing on the progress of new drug development. **Stocks Ranked Among the Top by Market Capitalization in the Industry** Gilead Sciences rose by 2.90%. Based on recent key news: 1. On January 7, Citibank identified Gilead Sciences as a top large-cap pick in the U.S. biopharmaceutical sector, emphasizing that its upcoming HIV treatment drug Yeztugo is a key growth driver. This news boosted the stock price. 2. On January 6, Gilead Sciences entered into a research collaboration agreement with OncoNano Medicine to evaluate the combination of OncoNano's ON-BOARD technology with Gilead's drug candidates. This collaboration could yield up to $300 million in revenue, enhancing market confidence in Gilead's future growth. 3. On January 6, Citibank raised Gilead Sciences' target price to $140, reflecting analysts' optimistic expectations for its future performance. The biopharmaceutical industry has performed strongly recently, with significant capital inflows ### Related Stocks - [VOR.US](https://longbridge.com/en/quote/VOR.US.md) ## Related News & Research - [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News](https://longbridge.com/en/news/288330248.md) - [UnitedHealth Just Raised Its Dividend 5%. Why You Should Buy UNH Stock Here.](https://longbridge.com/en/news/288782765.md) - [Unusual Trading in Kraft Heinz Call Options After CEO Interview - Is KHC Stock a Buy?](https://longbridge.com/en/news/288611991.md) - [Buy US stocks starting from 5 USDT? Binance launches over 8,000 US stocks and ETFs.](https://longbridge.com/en/news/288385798.md) - ['On fire': Blowout jobs report shows Trump's economy has held up under Iran pressures](https://longbridge.com/en/news/288873971.md)